Skip to content. Skip to navigation
Personal tools
  Members Area  

ANZCA

Sections
You are here: Home Events ANZCA Annual Scientific Meetings 2008 ASM Abstracts EC50 for LMA insertion using an effect site model during rapid wash-in of sevoflurane
Navigation
News
24-08-2008
New drug
A new drug has just been approved for use in Australia. SITAGLIPTIN (Januvia) is an oral drug for type 2 Diabetes mellitus. It is a new class of drug, a dipeptidyl peptidase (DPP-4) inhibitor. Sitagliptin is an 'incretin enhancer' that increases the levels of active incretin by inhibiting their metabolism by DPP-4, thus prolonging their effect in stimulating insulin release and decreasing glucagon secretion.
24-08-2008
The latest ANZCA e-newsletter has been emailed
The latest edition of ANZCA’s e-newsletter has now been emailed to Fellows, trainees and ANZCA staff.
21-08-2008
Fellowship Affairs
The first meeting of the Fellowship Affairs Committee was held on Friday, 15 August 2008. Chaired by Dr Margaret Cowling, the Committee oversees all matters directly pertinent to Fellows, including CPD, annual scientific meetings, Regional CME and SIG events, communications and professional issues
20-08-2008
RFT for Australian Clinical Quality Registries pilot projects
The Australian Commission on Safety and Quality in Health Care is seeking tenders from relevant organisations to test and validate the draft 'Operating Principles and Technical Standards for Australian Clinical Quality Registries'.
20-08-2008
Electricity & greenhouse emissions
You might wonder whether turning off the lights when not required actually saves energy. Thanks to the efforts of College staff, we have saved a massive 15 per cent greenhouse gas emissions over the last six months compared to last year. A lot of this can be attributed to turning off lights and switching to energy efficient flourescent light globes. The impact has been significant.
More news…
 
Document Actions

EC50 for LMA insertion using an effect site model during rapid wash-in of sevoflurane

Ross Kennedy1,2, Margaretta McKellow1, Christian Brett1, Richard French1

1Christchurch Hospital, Christchurch, New Zealand.
2University of Otago, Christchurch, Christchurch, New Zealand.

Background. The primary aim of this study was to determine the effect site EC50 for LMA insertion during rapid wash of sevoflurane using real time estimates of effect site levels. Previous slow wash-in studies have established an EC50 ("MAC-LMA") of 2.2 - 2.5vol% [1].

Methods. ASA 1 or 2 subjects. Mask induction with sevoflurane, 6 l/min fgf, 6% dial into an unprimed circuit. Real time estimation of effect site concentration using end-tidal as a measure of central compartment and an effect site equilibrium half time (t1/2ke0) of 3.2min based on studies using BIS as a measure of effect [2]. No other agents used.

LMA inserted at predetermined effect site, which for the first subject was 2.5vol%. Using the Dixon up-and-down method, if the subject responded the target level was increased by 0.2 vol% for the next subject. If no response the target level was decreased. The study continued until seven consecutive response/no response pairs occurred.

Results. 30 female subjects. Median age 39yr (range 22-66). The mean crossing point (calculated EC50) for the seven pairs was 1.6vol%. sd. 0.2vol%. Reprocessing the raw data with t1/2=2.0min gave a mean crossing point of 2.2 (sd 0.3) vol%, significantly different from the original analysis (p=0.001, CI of difference -0.9 to -0.3).

Conclusions. The appropriate effect site level for LMA insertion was reached more rapidly than suggested by BIS based studies. This may be due to differences inherent in having rapidly changing end-tidal and effect site values or reflect real differences in effect site equilibration times for the hypnotic and airway reflex suppressant effects of sevoflurane. These data also allow development of sevoflurane delivery and time based guidelines for LMA insertion.

References 1. Kodaka BJA 92:242; 2. Kennedy BJA 100:72; 3 Mourisse BJA 98:746